Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

Abha A. Gupta, Yueh Yun Chi, James R. Anderson, Elizabeth Lyden, Brenda Weigel, Carola A.S. Arndt, William H. Meyer, Abby Rosenberg, Douglas S. Hawkins

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: We sought to determine whether adolescents with metastatic alveolar rhabdomyosarcoma (ARMS) or embryonal RMS (ERMS) had a different event-free survival (EFS) compared with younger patients, and to identify treatment-related factors (adverse events, AEs) that may be associated with differences in outcome. Methods: The prevalence of AEs in adolescents older than 13 years was compared with that in patients less than or equal to 13 years of age (Fisher exact test) in patients enrolled onto ARST0431. EFS by age and histology was compared by log-rank test. Results: Of 109 patients, 60 (55%) were older than 13 years; they were more likely to have nausea (17 vs. 4%, P = 0.06) and pain (20 vs. 6%, P = 0.05) compared with younger patients. Adolescents were less likely to complete therapy (63 vs. 76%) and more likely to have unplanned dose modifications outside of protocol guidelines (23 vs. 2.7%). The 3-year EFS was 26% (95% confidence interval [CI]: 15-38) for adolescents compared with 46% (95% CI: 32-60) for those less than or equal to 13 years (P = 0.011). Forty-two (59%) adolescents with ARMS had a 3-year EFS of 13% (95% CI: 2-23) compared with 30% (95% CI: 10-51) for those less than or equal to 13 years (P = 0.032). EFS was comparable between older and younger patients with ERMS (64 vs. 55%, P = 0.53). Conclusions: Although there was a significant difference in EFS and protocol compliance by age, the differences in age-related toxicity are unlikely to account for this. Observed differences in pain and nausea by age could be real or be dependent on patient reporting of symptoms. Future studies in RMS should include patient-reported outcomes to better evaluate health-related quality of life.

Original languageEnglish (US)
JournalPediatric Blood and Cancer
DOIs
StateAccepted/In press - 2017

Fingerprint

Rhabdomyosarcoma
Disease-Free Survival
Drug Therapy
Alveolar Rhabdomyosarcoma
Confidence Intervals
Nausea
Guideline Adherence
Pain
Histology
Quality of Life
Guidelines
Therapeutics

Keywords

  • Adolescent
  • Chemotherapy
  • Rhabdomyosarcoma
  • Toxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma : A report from the Children's Oncology Group. / Gupta, Abha A.; Chi, Yueh Yun; Anderson, James R.; Lyden, Elizabeth; Weigel, Brenda; Arndt, Carola A.S.; Meyer, William H.; Rosenberg, Abby; Hawkins, Douglas S.

In: Pediatric Blood and Cancer, 2017.

Research output: Contribution to journalArticle

Gupta, Abha A. ; Chi, Yueh Yun ; Anderson, James R. ; Lyden, Elizabeth ; Weigel, Brenda ; Arndt, Carola A.S. ; Meyer, William H. ; Rosenberg, Abby ; Hawkins, Douglas S. / Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma : A report from the Children's Oncology Group. In: Pediatric Blood and Cancer. 2017.
@article{d3e9bfd66a854c2999f2f4b4efeb8817,
title = "Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group",
abstract = "Background: We sought to determine whether adolescents with metastatic alveolar rhabdomyosarcoma (ARMS) or embryonal RMS (ERMS) had a different event-free survival (EFS) compared with younger patients, and to identify treatment-related factors (adverse events, AEs) that may be associated with differences in outcome. Methods: The prevalence of AEs in adolescents older than 13 years was compared with that in patients less than or equal to 13 years of age (Fisher exact test) in patients enrolled onto ARST0431. EFS by age and histology was compared by log-rank test. Results: Of 109 patients, 60 (55{\%}) were older than 13 years; they were more likely to have nausea (17 vs. 4{\%}, P = 0.06) and pain (20 vs. 6{\%}, P = 0.05) compared with younger patients. Adolescents were less likely to complete therapy (63 vs. 76{\%}) and more likely to have unplanned dose modifications outside of protocol guidelines (23 vs. 2.7{\%}). The 3-year EFS was 26{\%} (95{\%} confidence interval [CI]: 15-38) for adolescents compared with 46{\%} (95{\%} CI: 32-60) for those less than or equal to 13 years (P = 0.011). Forty-two (59{\%}) adolescents with ARMS had a 3-year EFS of 13{\%} (95{\%} CI: 2-23) compared with 30{\%} (95{\%} CI: 10-51) for those less than or equal to 13 years (P = 0.032). EFS was comparable between older and younger patients with ERMS (64 vs. 55{\%}, P = 0.53). Conclusions: Although there was a significant difference in EFS and protocol compliance by age, the differences in age-related toxicity are unlikely to account for this. Observed differences in pain and nausea by age could be real or be dependent on patient reporting of symptoms. Future studies in RMS should include patient-reported outcomes to better evaluate health-related quality of life.",
keywords = "Adolescent, Chemotherapy, Rhabdomyosarcoma, Toxicity",
author = "Gupta, {Abha A.} and Chi, {Yueh Yun} and Anderson, {James R.} and Elizabeth Lyden and Brenda Weigel and Arndt, {Carola A.S.} and Meyer, {William H.} and Abby Rosenberg and Hawkins, {Douglas S.}",
year = "2017",
doi = "10.1002/pbc.26479",
language = "English (US)",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma

T2 - A report from the Children's Oncology Group

AU - Gupta, Abha A.

AU - Chi, Yueh Yun

AU - Anderson, James R.

AU - Lyden, Elizabeth

AU - Weigel, Brenda

AU - Arndt, Carola A.S.

AU - Meyer, William H.

AU - Rosenberg, Abby

AU - Hawkins, Douglas S.

PY - 2017

Y1 - 2017

N2 - Background: We sought to determine whether adolescents with metastatic alveolar rhabdomyosarcoma (ARMS) or embryonal RMS (ERMS) had a different event-free survival (EFS) compared with younger patients, and to identify treatment-related factors (adverse events, AEs) that may be associated with differences in outcome. Methods: The prevalence of AEs in adolescents older than 13 years was compared with that in patients less than or equal to 13 years of age (Fisher exact test) in patients enrolled onto ARST0431. EFS by age and histology was compared by log-rank test. Results: Of 109 patients, 60 (55%) were older than 13 years; they were more likely to have nausea (17 vs. 4%, P = 0.06) and pain (20 vs. 6%, P = 0.05) compared with younger patients. Adolescents were less likely to complete therapy (63 vs. 76%) and more likely to have unplanned dose modifications outside of protocol guidelines (23 vs. 2.7%). The 3-year EFS was 26% (95% confidence interval [CI]: 15-38) for adolescents compared with 46% (95% CI: 32-60) for those less than or equal to 13 years (P = 0.011). Forty-two (59%) adolescents with ARMS had a 3-year EFS of 13% (95% CI: 2-23) compared with 30% (95% CI: 10-51) for those less than or equal to 13 years (P = 0.032). EFS was comparable between older and younger patients with ERMS (64 vs. 55%, P = 0.53). Conclusions: Although there was a significant difference in EFS and protocol compliance by age, the differences in age-related toxicity are unlikely to account for this. Observed differences in pain and nausea by age could be real or be dependent on patient reporting of symptoms. Future studies in RMS should include patient-reported outcomes to better evaluate health-related quality of life.

AB - Background: We sought to determine whether adolescents with metastatic alveolar rhabdomyosarcoma (ARMS) or embryonal RMS (ERMS) had a different event-free survival (EFS) compared with younger patients, and to identify treatment-related factors (adverse events, AEs) that may be associated with differences in outcome. Methods: The prevalence of AEs in adolescents older than 13 years was compared with that in patients less than or equal to 13 years of age (Fisher exact test) in patients enrolled onto ARST0431. EFS by age and histology was compared by log-rank test. Results: Of 109 patients, 60 (55%) were older than 13 years; they were more likely to have nausea (17 vs. 4%, P = 0.06) and pain (20 vs. 6%, P = 0.05) compared with younger patients. Adolescents were less likely to complete therapy (63 vs. 76%) and more likely to have unplanned dose modifications outside of protocol guidelines (23 vs. 2.7%). The 3-year EFS was 26% (95% confidence interval [CI]: 15-38) for adolescents compared with 46% (95% CI: 32-60) for those less than or equal to 13 years (P = 0.011). Forty-two (59%) adolescents with ARMS had a 3-year EFS of 13% (95% CI: 2-23) compared with 30% (95% CI: 10-51) for those less than or equal to 13 years (P = 0.032). EFS was comparable between older and younger patients with ERMS (64 vs. 55%, P = 0.53). Conclusions: Although there was a significant difference in EFS and protocol compliance by age, the differences in age-related toxicity are unlikely to account for this. Observed differences in pain and nausea by age could be real or be dependent on patient reporting of symptoms. Future studies in RMS should include patient-reported outcomes to better evaluate health-related quality of life.

KW - Adolescent

KW - Chemotherapy

KW - Rhabdomyosarcoma

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85017110645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017110645&partnerID=8YFLogxK

U2 - 10.1002/pbc.26479

DO - 10.1002/pbc.26479

M3 - Article

C2 - 28333415

AN - SCOPUS:85017110645

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

ER -